medigraphic.com
ISSN 0188-9796 (Print)

2005, Number s1

<< Back Next >>

Rev Endocrinol Nutr 2005; 13 (s1)

Laboratory tests more commonly employed in the study of a patient with an endocrine disease

Espinosa de los Monteros SAL

Language: Spanish
References: 32
Page: 7-12
PDF size: 83.56 Kb.


Text Extraction

No abstract


REFERENCES

  1. Terzolo M, Pia A, Alin A, Osella G, Reimondo G, Bovio S et al. Adrenal incidentaloma: a new cause of the metabolic syndrome? J Clin Endocrinol Metab 2002; 87: 998-1003.

  2. Wu T, Machacelo D, Jiang N, Hao P. Urinary free cortisol and cortisone determined by high performance liquid chromatography in the diagnosis of Cushing’s syndrome. J Clin Endocrinol Metab 1997; 82: 151-5.

  3. Findling J, Raff H. Diagnosis and differential diagnosis of Cushing’s syndrome. Endocrinol Metab Clin North Am 2001; 30: 729-47.

  4. Nieman L, Cutler G. The sensitivity of the urine free cortisol measurement as screening test for Cushing’s syndrome. En: Programs and abstracts of the Endocrine Society 72nd Annual Meeting, Atlanta GA 1990; pp 822.

  5. Findling JW, Raff H, Aron DC. The low-dose dexamethasone suppression test: a reevaluation in patients with Cushing’s syndrome. J Clin Endocrinol Metab 2004; 89: 1222-6.

  6. Isidori AM, Kaltsas GA, Mohammed S et al. Discriminatory value of the low-dose dexamethasone suppression test in establishing the diagnosis and differential diagnosis of Cushing’s syndrome. J Clin Endocrinol Metab 2003; 88: 5299-306.

  7. Word P, Barth J, Freedman D, Perry L, Sheridan B. Evidence for the low dose dexamethasone suppression test to screen for Cushing’s syndrome, recommendations for a protocol for biochemistry laboratories. Ann Clin Bioche 1997; 34: 222-9.

  8. Gorges R, Knappe G, Herl H. Diagnosis of Cushing’s syndrome: Re-evaluation of midnight plasma cortisol vs urinary free cortisol and low-dose dexamethasone suppression test in a large patient group. J Endocrinol Invest 1999; 22: 241-49.

  9. Newell-Price J, Trainer P, Perry L et al. A single sleeping midnight cortisol has 100% sensitivity for the diagnosis of Cushing’s syndrome. Clin Endocrinol 1995; 43: 545-50.

  10. Putignano P, Toja P, Dubini A, Giraldi F, Corsello S, Cavagnini F. Midnight salivary cortisol vs urinary free and midnight serum cortisol as screening tests for Cushing’s syndrome. J Clin Endocrinol Metab 2003; 88: 4153-7.

  11. Yanovski J, Gordon C, Chrousos G, Nieman L. Corticotropin realizing hormone stimulation following low dose dexamethasone administration. A new test to distinguish Cushing’s syndrome from pseudo-Cushing states. JAMA 1993; 269: 2232-38.

  12. Papanicolaou D, Yanovski J, Cutler G, Chrousos G, Nieman L. A single midnight serum cortisol measurement distinguishes Cushing’s syndrome from pseudo-Cushing status. J Clin Endocrinol Metab 1998; 83: 1163-7.

  13. Moro M, Putignano P, Losa M, Invitti C, Maraschini C, Cavagnini F. The desmopressin test in the differential diagnosis between Cushing’s disease and pseudo-Cushing states. J Clin Endocrinol Metab 2000; 85: 3569-74.

  14. Lindsay J, Nieman L. Differential diagnosis and imaging in Cushing’s syndrome. Endocrinol Metab Clin NA 2005; 34: 403-21.

  15. Ilias I, Torpy D, Pacak N, Mullen N, Weley R, Nieman L. Cushing’s syndrome due to ectopic corticotropin secretion: twenty years’ experience at the National Institute of Health. J Clin Endocrinol Metab 2005: 90: 4955-4962.

  16. Raff H, Findling J. A physiologic approach to diagnosis of Cushing syndrome. Ann Intern Med 2003; 138: 980-991.

  17. Flack M, Oldfiel E, Cutler G, Zweing M, Malley J, Chrousos G et al. Urine free cortisol in the high dose dexamethasone suppression test for the differential diagnosis of the Cushing’s syndrome. Ann Intern Med 1992; 116: 211-17.

  18. Tyrrel J, Findling J, Aron D, Fitzgerald P, Forsham P. An overnight high dose dexamethasone suppression test for rapid differential diagnosis of Cushing’s syndrome. Ann Intern Med 1986; 104: 180-6.

  19. Dichek H, Nieman L, Oldfield E, Pass H, Malley J, Cutler G. A comparison of the standard high dose dexamethasone suppression test for the differential diagnosis of adrenocorticotropin dependent Cushing’s syndrome. J Clin Endocrinol Metab 1994; 78: 418-22.

  20. van den Bogaert D, de Herder W, de Jong F, Biemond P, van der Lely, Lamberts S. The continuous 7-hour intravenous dexamethasone suppression test in the differential diagnosis of ACTH-dependent Cushing’s syndrome. Clin Endocrinol 1999; 51: 193-8.

  21. Nieman L, Oldfield E, Wesley R, Chrousos G, Loriaux L, Cutler G. A simplified morning ovine corticotropin releasing hormone stimulation test for the differential diagnosis of adrenocorticotropin-dependent Cushing’s syndrome. J Clin Endocrinol Metab 1993; 77: 1308-12.

  22. Bates A, Van’t Hoff W, Jones J, Clayton R. An audit of outcome of treatment in acromegaly. Q J Med 1993; 86: 293-299.

  23. Haldaway I, Rajasoorya R, Gamble D. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 2004; 89: 667-674.

  24. Ayuk J, Clayton G, Holder M, Sheppard M, Stewart P, Bates A. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab 2004; 89: 1613-17.

  25. Giustina A, Barkan A, Casanueva F, Cavagnini F, Forman L, Ho K et al. Criteria for use of acromegaly: a consensus statement. J Clin Endocrinol Metab 2000; 85: 526-29.

  26. Freda P., Nuruzzaman A, Reyes C, Sondeen R, Post K. Significance of “abnormal” nadir growth hormone levels after oral glucose in postoperative patients with acromegaly in remission with normal insulin-like growth factor-I levels. J Clin Endocrinol Metab 2004; 89: 495-500.

  27. Biochemical assessment and long term monitoring in patients with acromegaly: statement from a joint consensus conference of the Growth hormone Research Society and the Pituitary Society. J Clin Endocrinol Metab 2004; 89: 3099-3102.

  28. Swearingen B, Barker FG, Katznelson L, Biller BM, Grinspoon S, Klibanski A et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 1998; 83: 3419-3426.

  29. Beauregard C, Truong U, Hardy J, Serri O. Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly. Clin Endocrinol (Oxf) 2003; 58: 86-92.

  30. Ayuk J, Clayton G, Holder M, Sheppard M, Stewart P, Bates A. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab 2004; 89: 1613-17.

  31. Espinosa de los Monteros AL, Mercado M, Sosa E, Lizama O, Guinto G, López B, García O et al. Changing patterns of insulin-like growth factor–I and glucose-suppressed growth hormone levels after pituitary surgery in patients with acromegaly. J Neurosurg 2002; 97: 287-292.

  32. Espinosa de los Monteros AL, Sosa E, Cheng S, Ochoa R, Sandoval C, Guinto G et al. Evaluation of biochemical activity in acromegalic patients after pituitary surgery: a critical analysis of patients who spontaneously change disease status. Clin Endocrinol (Oxf). En prensa




2020     |     www.medigraphic.com